Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 known ✓ | P03952 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 5/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.53 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 5/20 | 0.41 |
| ▸ | PLG | P00747 | 3/20 | 0.41 |
| ▸ | F10 | P00742 | 3/20 | 0.41 |
| ▸ | PLAT | P00750 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782636 | 0.98 | F2 (0.55) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL11226180 | 0.84 | F2 (0.57) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL10674543 | 0.82 | F2 (0.55) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL273175 | 0.82 | F2 (0.55) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL1999045 | 0.82 | F2 (0.59) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL28796971 | 0.81 | F2 (0.53) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL24891830 | 0.80 | KMT2A (0.64) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL7913893 | 0.80 | F2 (0.57) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL7922546 | 0.80 | F2 (0.57) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL211005 | 0.80 | F2 (0.57) | F2PRSS1PRSS2PRSS3TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115141284-A | Macromolecular derivative, preparation method and application thereof | 安庆市嘉欣医疗用品科技股份有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-117986161-A | Synthesis method of high-purity anti-hemagglutination medicament | 华仁医学研究(安徽)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-115141284-A | Macromolecular derivative, preparation method and application thereof | 安庆市嘉欣医疗用品科技股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20210403420-A1 | BENZOATE COMPOUND | SCOHIA PHARMA, INC. (JP) | 2021-12-30 | — | — | US | disclosed |
| CN-113683537-A | Crystal forms of camostat mesylate and solvates thereof, and preparation methods and applications of crystal forms and solvates thereof | 天津药物研究院有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-113683534-A | Crystal forms of camostat mesylate and solvates thereof, and preparation methods and applications of crystal forms and solvates thereof | 天津药物研究院有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-111803652-B | Use of a compound for treating acne in the preparation of a pharmaceutical or cosmetic composition for treating acne | 南通康是美生物科技有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-111544599-B | Compound for treating acne and application of compound for preparing medicines or cosmetics | 有术肌肤管理(深圳)有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-111803652-A | Use of a compound for treating acne in the preparation of a pharmaceutical or cosmetic composition for treating acne | 北京瀚梅生物科技有限公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-111544599-A | Compound for treating acne and application of compound for preparing medicines or cosmetics | 北京瀚梅生物科技有限公司 | 2020-08-18 | — | — | CN | disclosed |
| EP-0048433-A2 | Novel amidine compounds, process for producing same and anti-complement agent comprising them | TORII & CO., LTD. (JP) | 1982-03-31 | — | — | EP | disclosed |
| US-4310533-A | INHIBITING PLASMIN AND-OR TRYSIN ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-01-12 | — | — | US | disclosed |
| US-4283418-A | ANTIPLASMIN AND ANTITRYPSIN AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1981-08-11 | — | — | US | disclosed |
| US-4224342-A | ANTI-PLASMIN AND ANTI-TRYPSIN ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 1980-09-23 | — | — | US | disclosed |
| US-4179511-A | Antibacterial 3-(5-tetrazolyl) penam compounds | PFIZER INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4143039-A | ANTIBACTERIAL 3-(5-TETRAZOLYL)PENAM COMPOUNDS | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4115385-A | PENICILLINS | PFIZER INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-4021472-A | ANTIPLASMIN AND ANTITRYPSIN | ONO PHARMACEUTICAL CO., LTD. (JA) | 1977-05-03 | — | — | US | disclosed |
| US-3972872-A | BACTERICIDE, ANIMAL FEED SUPPLEMENT | PFIZER INC. (US) | 1976-08-03 | — | — | US | disclosed |
| US-3933797-A | 6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS | PFIZER INC. (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403420-A1 | BENZOATE COMPOUND | TMPRSS15, DPP4, DPP3 | KLKB1 1917/4885F2 1945/4885PRSS1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.